Retinal Disease Therapeutics Market By Indication (Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy, and Retinal Vein Occlusion), By Application (Hospital Pharmacy, Retail Pharmacy, and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2034

Retinal Disease Therapeutics Market was valued at US$ 13.4 Billion in 2024 and is projected to grow at a CAGR of 9.30 % to reach US$ 32.7 Billion by 2034.

Retina is a layer of nerve tissue lining the back of the eye. Retina receives light and converts it into neural signals, and sends these signals to the brain for visual recognition. The central part of the retina is known as macula, which is responsible for central vision. The remaining tissue outside the macula is responsible for peripheral vision. There are many types of retinal diseases. Some of these diseases involve only the macula such as age-related macular degeneration, macular pucker (epiretinal membrane), or macular hole; other diseases can impact the entire retina such as retinal detachment or diabetic retinopathy. The treatment of retinal diseases ranges from administration of eye drops to surgical procedures such as laser therapy, vitreoretinal surgery, and intraocular injection. All these procedures are aimed to preserve the integrity of the retina. 

Impact of Covid-19 pandemic on market

With the outbreak of the COVID-19, various businesses are at the forefront to combat this pandemic. The pandemic has hindered the industrial supply chain and also disrupted the product segment. Government across the countries has imposed strict lockdown to limit the spread of disease. Due to the pandemic all the activities are restricted which will adversely impact the retinal disease market. This report will quantify the impact of pandemic on retinal disease therapeutics market.

Rise in the incidence of eye-related diseases

There is an alarming rise in the incidence of eye-related diseases, especially in developed countries, which in turn is anticipated to drive the growth of the global retinal drugs market during the forecast period. According to an update from the American Academy of Ophthalmology in 2016, about 93 million people had diabetic retinopathy worldwide, of which 4.2 million patients were from the U.S. Increasing health education initiatives about eye diseases to seek early treatment and prevent visual impairment in emerging regions are further anticipated to fuel the expansion of the global market for retinal drugs during the forecast period.

Increasing awareness about eye disease

Several initiatives have been undertaken across the globe to spread awareness about diagnosis and treatment methods of ophthalmic diseases. The International Centre for Eye Health focuses on increasing awareness about eye health problems and treatment. The World Glaucoma Association has been arranging World Glaucoma Congress for the past six years to increase awareness and discussion about glaucoma treatment advancements. Macular Degeneration Association, Inc. arranges seminars every month across various places to increase treatment penetration for age-related macular degeneration (AMD). These initiatives are expected to increase the adoption of various treatment methods which in turn is projected to fuel the growth of the market.

The global retinal disease therapeutics market is segmented based on indication, application and region.

On the basis of indication, the global retinal disease therapeutics market is segmented into Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy, and Retinal Vein Occlusion.

Based on application, the global retinal disease therapeutics market is segmented into hospital pharmacy, retail pharmacy, and others.

Regional Insights:  

On region the global retinal disease therapeutics market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to account for a significant share of the market in terms of revenue. High research and development activities in the field of ophthalmic drugs, rising patient population, and high disposable income are factors which are attributed to the high market share of the region. According to data published by Nano Retina (member of the Rainbow Medical Group), in 2014, about 170 million people were affected with AMD worldwide, of which 15 million people were from the U.S. The number of people affected with AMD is expected to reach 288 million by 2040 globally.

Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2029. For the purpose of this study, has segmented the global retinal disease therapeutics market report based on indication, application, and region.

Retinal Disease Therapeutics Market, By Indication:

• Macular Degeneration
• Diabetic Macular Edema
• Diabetic Retinopathy
• Retinal Vein Occlusion

Retinal Disease Therapeutics Market, By Application:

• Hospital Pharmacy
• Retail Pharmacy
• Others

Retinal Disease Therapeutics Market, By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

 The key players operating in the global retinal disease therapeutics market includes Santen Pharmaceutical Co., Ltd., Regeneron Pharmaceuticals, Inc., Shire Plc, Bayer AG, Novartis International AG, Valeant Pharmaceuticals International, Inc., and Merck & Co., Inc. The market is especially characterized by collaborations and partnerships between the businesses and acquisitions of smaller players as a part of strategic expansion as well as launching their new product specimen. For instance, In April 2020, Novartis acquired Amblyotech, a US-based software startup, and will, in collaboration with Ubisoft and McGill University, pursue the development of the acquired digital technology for the treatment of amblyopia.

• Santen Pharmaceutical Co., Ltd.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

• Regeneron Pharmaceuticals, Inc.
• Shire Plc
• Bayer AG
• Novartis International AG
• Valeant Pharmaceuticals International, Inc.
• Merck & Co., Inc.